Cyclic amine sulfonamides as linkers in the design and synthesis of novel human β3 adrenergic receptor agonists
摘要:
Piperidine, pyrrolidine, and azetidine sulfonamides were examined as linkers in designing novel human beta(3) adrenergic receptor (beta(3)-AR) agonists. The azetidine derivative 37, and piperidine derivatives 7, 8, and 13 were found to be potent beta(3)-AR agonists and have good selectivity against beta(1)- and beta(2)-AR. (C) 2003 Elsevier Science Ltd. All rights reserved.
完成了4,5,6,7-四氢噻吩并[2,3- c ]吡啶基的β-氨基腈,β-氨基羧酰胺及其(硫代)尿素和环状衍生物的制备和细胞毒性表征。按照涉及Gewald三组分反应(G-3CR)和路易斯酸催化的异(硫)氰酸酯偶联的合成路线,制备了30种化合物用于抗肿瘤评估。对于衍生化,催化量的CuOAc 2(20 mol%)对于提高噻吩或异氰酸酯的C-2氨基官能团的反应性至关重要。合成的类似物在低微摩尔范围内显示出对A549和K562癌细胞系的弱至中度抗肿瘤活性。
Cyclamine sulfonamides as beta-3 adrenergic receptor agonists
申请人:American Home Products Corporation
公开号:US20020022605A1
公开(公告)日:2002-02-21
This invention provides compounds of Formula I having the structure
1
wherein R
1
, R
2
, R
3
, W, X, and Z are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
申请人:Wyeth
公开号:US20030027797A1
公开(公告)日:2003-02-06
This invention provides compounds of Formula I having the structure
1
wherein R
1
, R
2
, R
3
, W, X, and Z are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
Cyclylamine sulfonamides as &bgr;3-adrenergic receptor agonists
申请人:Wyeth
公开号:US06649603B2
公开(公告)日:2003-11-18
This invention provides compounds of Formula I having the structure
wherein R1, R2, R3, W, X, and Z are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
Cyclamine sulfonamides as &bgr;-3 adrenergic receptor agonists
申请人:Wyeth
公开号:US06498170B2
公开(公告)日:2002-12-24
This invention provides compounds of Formula I having the structure
wherein R1, R2, R3, W, X, and Z are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
A compound or its pharmaceutically acceptable salt, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula II, wherein the R group substituents, D, F, X, W and A are defined within.
本发明公开了一种化合物或其药学上可接受的盐、组合物和方法,可提供镇痛和减轻炎症。一种考虑使用的化合物具有与式 II 相对应的结构,其中 R 基取代基、D、F、X、W 和 A 在式 II 中定义。